← NewsAll
Amgen's MariTide reports two-year weight loss maintenance
Summary
Amgen said patients on its experimental drug MariTide maintained weight loss for two years, reporting topline results from a phase 2 study at the JPMorgan Healthcare Conference; the company did not release detailed data.
Content
Amgen said patients taking its experimental drug MariTide maintained weight loss for two years, and the company presented this as topline results from a phase 2 study. The announcement was made at the JPMorgan Healthcare Conference. Amgen did not release detailed efficacy or safety data alongside the topline statement. The company is discussed in the context of seeking a place in obesity treatment research.
Key facts:
- Amgen reported that patients on MariTide maintained weight loss for two years.
- The result was described as topline from a phase 2 study.
- Amgen presented the finding at the JPMorgan Healthcare Conference.
- No detailed data were released with the topline announcement.
Summary:
The announcement indicates a positive topline outcome for MariTide in the phase 2 study and is noted alongside Amgen's broader interest in obesity treatments. Detailed data on efficacy and safety have not been provided. Undetermined at this time.
